Elevated adenosine signaling via adenosine A2B receptor induces normal and sickle erythrocyte sphingosine kinase 1 activity

Blood

Volumn 125, Issue 10, 2015, Pages 1643-1652

  Sun, Kaiqi ^a,b   Zhang, Yujin ^a   Bogdanov, Mikhail V ^a   Wu, Hongyu ^a   Song, Anren ^a   Li, Jessica ^a   Dowhan, William ^a   Idowu, Modupe ^a   Juneja, Harinder S ^a   Molina, Jose G ^a   Blackburn, Michael R ^a,b   Kellems, Rodney E ^a,b   Xia, Yang ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ADENOSINE; ADENOSINE A2B RECEPTOR; ADENOSINE DEAMINASE; ANGIOTENSIN II; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIN 1; FORSKOLIN; MACROGOL; MITOGEN ACTIVATED PROTEIN KINASE 1; SPHINGOSINE KINASE 1; TUMOR NECROSIS FACTOR ALPHA; ADENOSINE 5' (N ETHYLCARBOXAMIDE); HEMOGLOBIN S; PHOSPHOTRANSFERASE; SPHINGOSINE KINASE;

ADENOSINE DEAMINASE DEFICIENCY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME THERAPY; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SICKLE CELL; SIGNAL TRANSDUCTION; WESTERN BLOTTING; AGAMMAGLOBULINEMIA; ANIMAL; BIOLOGICAL MODEL; BLOOD; CELL CULTURE; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; ERYTHROCYTE; ERYTHROCYTE DISORDER; GENETICS; KNOCKOUT MOUSE; METABOLISM; SEVERE COMBINED IMMUNODEFICIENCY; SICKLE CELL ANEMIA; TRANSGENIC MOUSE;

ADENOSINE; ADENOSINE DEAMINASE; ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); AGAMMAGLOBULINEMIA; ANEMIA, SICKLE CELL; ANIMALS; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ERYTHROCYTES; ERYTHROCYTES, ABNORMAL; HEMOGLOBIN, SICKLE; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RECEPTOR, ADENOSINE A2B; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION;

EID: 84979866008     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-595751     Document Type: Article

References (54)

1. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4(5):397-407.
2. Murata N, Sato K, Kon J, Tomura H, Okajima F. Quantitative measurement of sphingosine 1-phosphate by radioreceptor-binding assay. Anal Biochem. 2000;282(1):115-120.
3. Sensken SC, Bode C, Nagarajan M, Peest U, Pabst O, Gräler MH. Redistribution of sphingosine 1-phosphate by sphingosine kinase 2 contributes to lymphopenia. J Immunol. 2010;184(8): 4133-4142.
4. Andréani P, Gräler MH. Comparative quantification of sphingolipids and analogs in biological samples by high-performance liquid chromatography after chloroform extraction. Anal Biochem. 2006;358(2):239-246.
5. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007; 316(5822):295-298.
6. Camerer E, Regard JB, Cornelissen I, et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest. 2009; 119(7):1871-1879.
7. Ishii M, Egen JG, Klauschen F, et al. Sphingosine- 1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature. 2009; 458(7237):524-528.
8. Visentin B, Vekich JA, Sibbald BJ, et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell. 2006;9(3):225-238.
9. Cinamon G, Zachariah MA, Lam OM, Foss FW Jr, Cyster JG. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol. 2008;9(1):54-62.
10. Bode C, Sensken SC, Peest U, et al. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem. 2010; 109(6):1232-1243.
11. Hänel P, Andréani P, Gräler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J. 2007;21(4):1202-1209.
12. Yang L, Yatomi Y, Miura Y, Satoh K, Ozaki Y. Metabolism and functional effects of sphingolipids in blood cells. Br J Haematol. 1999;107(2): 282-293.
13. Ito K, Anada Y, Tani M, et al. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem Biophys Res Commun. 2007;357(1): 212-217.
14. Sankala HM, Hait NC, Paugh SW, et al. Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res. 2007;67(21):10466-10474.
15. Kihara A, Igarashi Y. Production and release of sphingosine 1-phosphate and the phosphorylated form of the immunomodulator FTY720. Biochim Biophys Acta. 2008;1781(9):496-502.
16. Allende ML, Sasaki T, Kawai H, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem. 2004; 279(50):52487-52492.
17. Zhang Y, Berka V, Song A, et al. Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. J Clin Invest. 2014;124(6):2750-2761.
18. Blackburn MR, Datta SK, Kellems RE. Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem. 1998;273(9):5093-5100.
19. Blackburn MR, Datta SK, Wakamiya M, Vartabedian BS, Kellems RE. Metabolic and immunologic consequences of limited adenosine deaminase expression in mice. J Biol Chem. 1996;271(25):15203-15210.
20. Zhou Y, Mohsenin A, Morschl E, et al. Enhanced airway inflammation and remodeling in adenosine deaminase-deficient mice lacking the A2B adenosine receptor. J Immunol. 2009;182(12): 8037-8046.
21. Pászty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278(5339):876-878.
22. Chunn JL, Mohsenin A, Young HW, et al. Partially adenosine deaminase-deficient mice develop pulmonary fibrosis in association with adenosine elevations. Am J Physiol Lung Cell Mol Physiol. 2006;290(3):L579-L587.
23. Chunn JL, Molina JG, Mi T, Xia Y, Kellems RE, Blackburn MR. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J Immunol. 2005;175(3):1937-1946.
24. Chunn JL, Young HW, Banerjee SK, Colasurdo GN, Blackburn MR. Adenosine-dependent airway inflammation and hyperresponsiveness in partially adenosine deaminase-deficient mice. J Immunol. 2001;167(8):4676-4685.
25. Zhang Y, Dai Y, Wen J, et al. Detrimental effects of adenosine signaling in sickle cell disease. Nat Med. 2011;17(1):79-86.
26. Pertoft H, Laurent TC, Låås T, Kågedal L. Density gradients prepared from colloidal silica particles coated by polyvinylpyrrolidone (Percoll). Anal Biochem. 1978;88(1):271-282.
27. Aldrich MB, Blackburn MR, Datta SK, Kellems RE. Adenosine deaminase-deficient mice: models for the study of lymphocyte development and adenosine signaling. Adv Exp Med Biol. 2000; 486:57-63.
28. Olivera A, Kohama T, Tu Z, Milstien S, Spiegel S. Purification and characterization of rat kidney sphingosine kinase. J Biol Chem. 1998;273(20): 12576-12583.
29. Johnson KR, Becker KP, Facchinetti MM, Hannun YA, Obeid LM. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12- myristate 13-acetate (PMA). J Biol Chem. 2002; 277(38):35257-35262.
30. Pettus BJ, Bielawski J, Porcelli AM, et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J. 2003;17(11):1411-1421.
31. Raymond MN, Bole-Feysot C, Banno Y, Tanfin Z, Robin P. Endothelin-1 inhibits apoptosis through a sphingosine kinase 1-dependent mechanism in uterine leiomyoma ELT3 cells. Endocrinology. 2006;147(12):5873-5882.
32. Leiber D, Banno Y, Tanfin Z. Exogenous sphingosine 1-phosphate and sphingosine kinase activated by endothelin-1 induced myometrial contraction through differential mechanisms. Am J Physiol Cell Physiol. 2007;292(1):C240-C250.
33. Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci. 2011; 36(2):97-107.
34. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006; 5(3):247-264.
35. Fredholm BB, AP IJ, Jacobson KA, Linden J, Muller CE. International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors-an update. Pharmacol. Rev Mar. 2011;63(1):1-34.
36. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53(4):527-552.
37. Dai Y, Zhang W, Wen J, Zhang Y, Kellems RE, Xia Y. A2B adenosine receptor-mediated induction of IL-6 promotes CKD. J Am Soc Nephrol. 2011;22(5):890-901.
38. Grant MB, Davis MI, Caballero S, Feoktistov I, Biaggioni I, Belardinelli L. Proliferation, migration, and ERK activation in human retinal endothelial cells through A(2B) adenosine receptor stimulation. Invest Ophthalmol Vis Sci. 2001; 42(9):2068-2073.
39. Pitson SM, Moretti PA, Zebol JR, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 2003;22(20): 5491-5500.
40. Maceyka M, Harikumar KB, Milstien S, Spiegel S. Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol. 2012;22(1):50-60.
41. Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O. Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res. 2008;68(20):8635-8642.
42. Awojoodu AO, Keegan PM, Lane AR, et al. Acid sphingomyelinase is activated in sickle cell erythrocytes and contributes to inflammatory microparticle generation in SCD. Blood. 2014; 124(12):1941-1950.
43. Wallace KL, Linden J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood. 2010;116(23):5010-5020.
44. Sun K, Xia Y. New insights into sickle cell disease: a disease of hypoxia. Curr Opin Hematol. 2013; 20(3):215-221.
45. Fredholm BB. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differ. 2007;14(7):1315-1323.
46. Eltzschig HK, Thompson LF, Karhausen J, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood. 2004;104(13):3986-3992.
47. Eltzschig HK, Ibla JC, Furuta GT, et al. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med. 2003;198(5):783-796.
48. Karmouty-Quintana H, Zhong H, Acero L, et al. The A2B adenosine receptor modulates pulmonary hypertension associated with interstitial lung disease. FASEB J. 2012;26(6): 2546-2557.
49. Zhou Y, Schneider DJ, Blackburn MR. Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther. 2009;123(1):105-116.
50. Wen J, Grenz A, Zhang Y, et al. A2B adenosine receptor contributes to penile erection via PI3K/ AKT signaling cascade-mediated eNOS activation. FASEB J. 2011;25(8):2823-2830.
51. Wen J, Jiang X, Dai Y, et al. Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J Sex Med. 2010;7(9):3011-3022.
52. Huang WC, Nagahashi M, Terracina KP, Takabe K. Emerging role of sphingosine-1- phosphate in inflammation, cancer, and lymphangiogenesis. Biomolecules. 2013;3(3): 408-434.
53. Thuy AV, Reimann CM, Hemdan NY, Gräler MH. Sphingosine 1-phosphate in blood: function, metabolism, and fate. Cell Physiol Biochem. 2014;34(1):158-171.
54. Ulrych T, Böhm A, Polzin A, et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost. 2011;9(4):790-798.